BriaCell Therapeutics Corp (NASDAQ:BCTX) does about 4.80M shares in volume on a normal day but saw 800815 shares change hands in the recent trading day. The company now has a market cap of 29.83M USD. Its current market price is $0.83, marking a decrease of -5.95% compared to the previous close of $0.88. The 52 week high reached by this stock is $5.97 whilst the lowest price level in 52 weeks is $0.46.
BriaCell Therapeutics Corp (BCTX) has a 20-day trading average at $0.9205 and the current price is -86.06% off the 52-week high compared with 79.34% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.7981 and its 200-day simple moving average is $1.8289. If we look at the stock’s price movements over the week, volatility stands at 8.44%, which increases to 17.27% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 48.22 to suggest the stock is neutral.
The consensus objective for the share price is $15.00, suggesting that the stock has a potential upside of 94.47% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 14, 2022 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $25.
The current price level is -9.56%, 4.29%, and -54.49% away from its SMA20, SMA50, and SMA200 respectively, with the BCTX price moving below the 50-day SMA on current market day. BriaCell Therapeutics Corp (BCTX) stock is down -4.57% over the week and -32.88% over the past month. Its price is -85.77% year-to-date and -78.04% over the past year.
The stock last released its quarterly earnings report for quarter ended 7/31/2024, with the company’s earnings per share (EPS) of 0.37 above consensus estimates by 0.55. The company’s next earnings report forecasts estimating quarterly EPS at -0.3 and -0.92 for whole year.
To reach the target analysts have set, the stock logically needs to grow 94.47 percent from here.
The company has a return on equity of -202.12%. The beta has a value of 1.35.
